nodes	percent_of_prediction	percent_of_DWPC	metapath
Zalcitabine—Cytarabine—lymphatic system cancer	0.432	1	CrCtD
Zalcitabine—Lamivudine—Cytarabine—lymphatic system cancer	0.092	0.355	CrCrCtD
Zalcitabine—Gemcitabine—Cytarabine—lymphatic system cancer	0.092	0.355	CrCrCtD
Zalcitabine—SLC29A1—Fludarabine—lymphatic system cancer	0.0741	0.271	CbGbCtD
Zalcitabine—DCK—Fludarabine—lymphatic system cancer	0.0687	0.251	CbGbCtD
Zalcitabine—SLC29A1—Cytarabine—lymphatic system cancer	0.0506	0.185	CbGbCtD
Zalcitabine—DCK—Cytarabine—lymphatic system cancer	0.0469	0.171	CbGbCtD
Zalcitabine—Cytarabine—Fludarabine—lymphatic system cancer	0.0405	0.156	CrCrCtD
Zalcitabine—Decitabine—Cytarabine—lymphatic system cancer	0.0346	0.133	CrCrCtD
Zalcitabine—SLC22A7—Methotrexate—lymphatic system cancer	0.00546	0.0199	CbGbCtD
Zalcitabine—CYP3A5—Teniposide—lymphatic system cancer	0.00545	0.0199	CbGbCtD
Zalcitabine—CYP2C9—Teniposide—lymphatic system cancer	0.00365	0.0134	CbGbCtD
Zalcitabine—CYP3A7—Vincristine—lymphatic system cancer	0.0035	0.0128	CbGbCtD
Zalcitabine—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0035	0.0128	CbGbCtD
Zalcitabine—CYP3A5—Vincristine—lymphatic system cancer	0.00262	0.00959	CbGbCtD
Zalcitabine—SLC22A6—Methotrexate—lymphatic system cancer	0.00232	0.00848	CbGbCtD
Zalcitabine—CYP3A4—Cytarabine—lymphatic system cancer	0.00216	0.00789	CbGbCtD
Zalcitabine—CYP3A4—Teniposide—lymphatic system cancer	0.00213	0.00777	CbGbCtD
Zalcitabine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.00149	0.00543	CbGbCtD
Zalcitabine—CYP3A4—Vincristine—lymphatic system cancer	0.00102	0.00374	CbGbCtD
Zalcitabine—Chills—Bleomycin—lymphatic system cancer	7.02e-05	0.00196	CcSEcCtD
Zalcitabine—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	6.93e-05	0.00194	CcSEcCtD
Zalcitabine—Alopecia—Bleomycin—lymphatic system cancer	6.91e-05	0.00193	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	6.91e-05	0.00193	CcSEcCtD
Zalcitabine—Jaundice—Mitoxantrone—lymphatic system cancer	6.89e-05	0.00193	CcSEcCtD
Zalcitabine—Urticaria—Teniposide—lymphatic system cancer	6.85e-05	0.00192	CcSEcCtD
Zalcitabine—Glossitis—Methotrexate—lymphatic system cancer	6.83e-05	0.00191	CcSEcCtD
Zalcitabine—Body temperature increased—Teniposide—lymphatic system cancer	6.82e-05	0.00191	CcSEcCtD
Zalcitabine—Abdominal pain—Teniposide—lymphatic system cancer	6.82e-05	0.00191	CcSEcCtD
Zalcitabine—Hallucination—Carmustine—lymphatic system cancer	6.79e-05	0.0019	CcSEcCtD
Zalcitabine—Hyperuricaemia—Methotrexate—lymphatic system cancer	6.79e-05	0.0019	CcSEcCtD
Zalcitabine—Dyspnoea—Fludarabine—lymphatic system cancer	6.76e-05	0.00189	CcSEcCtD
Zalcitabine—Dyspepsia—Fludarabine—lymphatic system cancer	6.67e-05	0.00187	CcSEcCtD
Zalcitabine—Ulcer—Methotrexate—lymphatic system cancer	6.66e-05	0.00186	CcSEcCtD
Zalcitabine—Sinusitis—Mitoxantrone—lymphatic system cancer	6.63e-05	0.00186	CcSEcCtD
Zalcitabine—Decreased appetite—Fludarabine—lymphatic system cancer	6.59e-05	0.00184	CcSEcCtD
Zalcitabine—Visual impairment—Carmustine—lymphatic system cancer	6.58e-05	0.00184	CcSEcCtD
Zalcitabine—Fatigue—Fludarabine—lymphatic system cancer	6.54e-05	0.00183	CcSEcCtD
Zalcitabine—Inflammation—Methotrexate—lymphatic system cancer	6.49e-05	0.00182	CcSEcCtD
Zalcitabine—Hallucination—Vincristine—lymphatic system cancer	6.49e-05	0.00182	CcSEcCtD
Zalcitabine—Pain—Fludarabine—lymphatic system cancer	6.48e-05	0.00181	CcSEcCtD
Zalcitabine—Blood uric acid increased—Methotrexate—lymphatic system cancer	6.41e-05	0.0018	CcSEcCtD
Zalcitabine—Eye disorder—Carmustine—lymphatic system cancer	6.38e-05	0.00179	CcSEcCtD
Zalcitabine—Rhinitis—Mitoxantrone—lymphatic system cancer	6.36e-05	0.00178	CcSEcCtD
Zalcitabine—Hypersensitivity—Teniposide—lymphatic system cancer	6.35e-05	0.00178	CcSEcCtD
Zalcitabine—Hepatitis—Mitoxantrone—lymphatic system cancer	6.35e-05	0.00178	CcSEcCtD
Zalcitabine—Flushing—Carmustine—lymphatic system cancer	6.34e-05	0.00177	CcSEcCtD
Zalcitabine—Ill-defined disorder—Bleomycin—lymphatic system cancer	6.32e-05	0.00177	CcSEcCtD
Zalcitabine—Pharyngitis—Mitoxantrone—lymphatic system cancer	6.3e-05	0.00176	CcSEcCtD
Zalcitabine—Anaemia—Bleomycin—lymphatic system cancer	6.29e-05	0.00176	CcSEcCtD
Zalcitabine—Feeling abnormal—Fludarabine—lymphatic system cancer	6.25e-05	0.00175	CcSEcCtD
Zalcitabine—Asthenia—Teniposide—lymphatic system cancer	6.19e-05	0.00173	CcSEcCtD
Zalcitabine—Melaena—Methotrexate—lymphatic system cancer	6.15e-05	0.00172	CcSEcCtD
Zalcitabine—Malaise—Bleomycin—lymphatic system cancer	6.14e-05	0.00172	CcSEcCtD
Zalcitabine—Pruritus—Teniposide—lymphatic system cancer	6.1e-05	0.00171	CcSEcCtD
Zalcitabine—Arrhythmia—Carmustine—lymphatic system cancer	6.1e-05	0.00171	CcSEcCtD
Zalcitabine—Leukopenia—Bleomycin—lymphatic system cancer	6.1e-05	0.00171	CcSEcCtD
Zalcitabine—Depressed level of consciousness—Methotrexate—lymphatic system cancer	6.08e-05	0.0017	CcSEcCtD
Zalcitabine—Alopecia—Carmustine—lymphatic system cancer	6.03e-05	0.00169	CcSEcCtD
Zalcitabine—Skin exfoliation—Methotrexate—lymphatic system cancer	6.01e-05	0.00168	CcSEcCtD
Zalcitabine—Body temperature increased—Fludarabine—lymphatic system cancer	5.99e-05	0.00168	CcSEcCtD
Zalcitabine—Vaginal infection—Methotrexate—lymphatic system cancer	5.95e-05	0.00166	CcSEcCtD
Zalcitabine—Cough—Bleomycin—lymphatic system cancer	5.94e-05	0.00166	CcSEcCtD
Zalcitabine—Diarrhoea—Teniposide—lymphatic system cancer	5.9e-05	0.00165	CcSEcCtD
Zalcitabine—Myalgia—Bleomycin—lymphatic system cancer	5.8e-05	0.00162	CcSEcCtD
Zalcitabine—Alopecia—Vincristine—lymphatic system cancer	5.76e-05	0.00161	CcSEcCtD
Zalcitabine—Back pain—Carmustine—lymphatic system cancer	5.75e-05	0.00161	CcSEcCtD
Zalcitabine—Discomfort—Bleomycin—lymphatic system cancer	5.73e-05	0.0016	CcSEcCtD
Zalcitabine—Chills—Mitoxantrone—lymphatic system cancer	5.7e-05	0.00159	CcSEcCtD
Zalcitabine—Bladder pain—Methotrexate—lymphatic system cancer	5.69e-05	0.00159	CcSEcCtD
Zalcitabine—Urine output increased—Methotrexate—lymphatic system cancer	5.69e-05	0.00159	CcSEcCtD
Zalcitabine—Arrhythmia—Mitoxantrone—lymphatic system cancer	5.67e-05	0.00159	CcSEcCtD
Zalcitabine—Alopecia—Mitoxantrone—lymphatic system cancer	5.61e-05	0.00157	CcSEcCtD
Zalcitabine—Confusional state—Bleomycin—lymphatic system cancer	5.6e-05	0.00157	CcSEcCtD
Zalcitabine—Vision blurred—Carmustine—lymphatic system cancer	5.6e-05	0.00157	CcSEcCtD
Zalcitabine—Hypersensitivity—Fludarabine—lymphatic system cancer	5.58e-05	0.00156	CcSEcCtD
Zalcitabine—Tremor—Carmustine—lymphatic system cancer	5.57e-05	0.00156	CcSEcCtD
Zalcitabine—Oedema—Bleomycin—lymphatic system cancer	5.56e-05	0.00156	CcSEcCtD
Zalcitabine—Infection—Bleomycin—lymphatic system cancer	5.52e-05	0.00155	CcSEcCtD
Zalcitabine—Anaemia—Carmustine—lymphatic system cancer	5.49e-05	0.00154	CcSEcCtD
Zalcitabine—Back pain—Vincristine—lymphatic system cancer	5.49e-05	0.00154	CcSEcCtD
Zalcitabine—Vomiting—Teniposide—lymphatic system cancer	5.48e-05	0.00153	CcSEcCtD
Zalcitabine—Agitation—Carmustine—lymphatic system cancer	5.46e-05	0.00153	CcSEcCtD
Zalcitabine—Thrombocytopenia—Bleomycin—lymphatic system cancer	5.44e-05	0.00152	CcSEcCtD
Zalcitabine—Asthenia—Fludarabine—lymphatic system cancer	5.44e-05	0.00152	CcSEcCtD
Zalcitabine—Rash—Teniposide—lymphatic system cancer	5.44e-05	0.00152	CcSEcCtD
Zalcitabine—Dermatitis—Teniposide—lymphatic system cancer	5.43e-05	0.00152	CcSEcCtD
Zalcitabine—Dysgeusia—Mitoxantrone—lymphatic system cancer	5.41e-05	0.00151	CcSEcCtD
Zalcitabine—Headache—Teniposide—lymphatic system cancer	5.4e-05	0.00151	CcSEcCtD
Zalcitabine—Pruritus—Fludarabine—lymphatic system cancer	5.36e-05	0.0015	CcSEcCtD
Zalcitabine—Lymphadenopathy—Methotrexate—lymphatic system cancer	5.36e-05	0.0015	CcSEcCtD
Zalcitabine—Back pain—Mitoxantrone—lymphatic system cancer	5.35e-05	0.0015	CcSEcCtD
Zalcitabine—Leukopenia—Carmustine—lymphatic system cancer	5.32e-05	0.00149	CcSEcCtD
Zalcitabine—Anorexia—Bleomycin—lymphatic system cancer	5.3e-05	0.00148	CcSEcCtD
Zalcitabine—Diabetes mellitus—Methotrexate—lymphatic system cancer	5.26e-05	0.00147	CcSEcCtD
Zalcitabine—Anaemia—Vincristine—lymphatic system cancer	5.24e-05	0.00147	CcSEcCtD
Zalcitabine—Agitation—Vincristine—lymphatic system cancer	5.21e-05	0.00146	CcSEcCtD
Zalcitabine—Vision blurred—Mitoxantrone—lymphatic system cancer	5.21e-05	0.00146	CcSEcCtD
Zalcitabine—Polyuria—Methotrexate—lymphatic system cancer	5.21e-05	0.00146	CcSEcCtD
Zalcitabine—Diarrhoea—Fludarabine—lymphatic system cancer	5.19e-05	0.00145	CcSEcCtD
Zalcitabine—Convulsion—Carmustine—lymphatic system cancer	5.15e-05	0.00144	CcSEcCtD
Zalcitabine—Hypertension—Carmustine—lymphatic system cancer	5.13e-05	0.00144	CcSEcCtD
Zalcitabine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	5.13e-05	0.00144	CcSEcCtD
Zalcitabine—Anaemia—Mitoxantrone—lymphatic system cancer	5.11e-05	0.00143	CcSEcCtD
Zalcitabine—Vertigo—Vincristine—lymphatic system cancer	5.1e-05	0.00143	CcSEcCtD
Zalcitabine—Leukopenia—Vincristine—lymphatic system cancer	5.08e-05	0.00142	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	5.06e-05	0.00142	CcSEcCtD
Zalcitabine—Myalgia—Carmustine—lymphatic system cancer	5.06e-05	0.00142	CcSEcCtD
Zalcitabine—Anxiety—Carmustine—lymphatic system cancer	5.04e-05	0.00141	CcSEcCtD
Zalcitabine—Malaise—Mitoxantrone—lymphatic system cancer	4.98e-05	0.00139	CcSEcCtD
Zalcitabine—Dyspnoea—Bleomycin—lymphatic system cancer	4.95e-05	0.00139	CcSEcCtD
Zalcitabine—Renal failure acute—Methotrexate—lymphatic system cancer	4.95e-05	0.00139	CcSEcCtD
Zalcitabine—Leukopenia—Mitoxantrone—lymphatic system cancer	4.95e-05	0.00138	CcSEcCtD
Zalcitabine—Convulsion—Vincristine—lymphatic system cancer	4.92e-05	0.00138	CcSEcCtD
Zalcitabine—Hypertension—Vincristine—lymphatic system cancer	4.9e-05	0.00137	CcSEcCtD
Zalcitabine—Confusional state—Carmustine—lymphatic system cancer	4.89e-05	0.00137	CcSEcCtD
Zalcitabine—Oedema—Carmustine—lymphatic system cancer	4.85e-05	0.00136	CcSEcCtD
Zalcitabine—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	4.85e-05	0.00136	CcSEcCtD
Zalcitabine—Decreased appetite—Bleomycin—lymphatic system cancer	4.83e-05	0.00135	CcSEcCtD
Zalcitabine—Myalgia—Vincristine—lymphatic system cancer	4.83e-05	0.00135	CcSEcCtD
Zalcitabine—Cough—Mitoxantrone—lymphatic system cancer	4.82e-05	0.00135	CcSEcCtD
Zalcitabine—Infection—Carmustine—lymphatic system cancer	4.82e-05	0.00135	CcSEcCtD
Zalcitabine—Vomiting—Fludarabine—lymphatic system cancer	4.82e-05	0.00135	CcSEcCtD
Zalcitabine—Convulsion—Mitoxantrone—lymphatic system cancer	4.79e-05	0.00134	CcSEcCtD
Zalcitabine—Rash—Fludarabine—lymphatic system cancer	4.78e-05	0.00134	CcSEcCtD
Zalcitabine—Dermatitis—Fludarabine—lymphatic system cancer	4.77e-05	0.00134	CcSEcCtD
Zalcitabine—Hypertension—Mitoxantrone—lymphatic system cancer	4.77e-05	0.00134	CcSEcCtD
Zalcitabine—Pain—Bleomycin—lymphatic system cancer	4.75e-05	0.00133	CcSEcCtD
Zalcitabine—Thrombocytopenia—Carmustine—lymphatic system cancer	4.75e-05	0.00133	CcSEcCtD
Zalcitabine—Headache—Fludarabine—lymphatic system cancer	4.75e-05	0.00133	CcSEcCtD
Zalcitabine—Tachycardia—Carmustine—lymphatic system cancer	4.73e-05	0.00133	CcSEcCtD
Zalcitabine—Myalgia—Mitoxantrone—lymphatic system cancer	4.7e-05	0.00132	CcSEcCtD
Zalcitabine—Arthralgia—Mitoxantrone—lymphatic system cancer	4.7e-05	0.00132	CcSEcCtD
Zalcitabine—Anxiety—Mitoxantrone—lymphatic system cancer	4.69e-05	0.00131	CcSEcCtD
Zalcitabine—Discomfort—Mitoxantrone—lymphatic system cancer	4.65e-05	0.0013	CcSEcCtD
Zalcitabine—Oedema—Vincristine—lymphatic system cancer	4.63e-05	0.0013	CcSEcCtD
Zalcitabine—Anorexia—Carmustine—lymphatic system cancer	4.62e-05	0.00129	CcSEcCtD
Zalcitabine—Infection—Vincristine—lymphatic system cancer	4.6e-05	0.00129	CcSEcCtD
Zalcitabine—Feeling abnormal—Bleomycin—lymphatic system cancer	4.58e-05	0.00128	CcSEcCtD
Zalcitabine—Osteoarthritis—Methotrexate—lymphatic system cancer	4.57e-05	0.00128	CcSEcCtD
Zalcitabine—Confusional state—Mitoxantrone—lymphatic system cancer	4.55e-05	0.00127	CcSEcCtD
Zalcitabine—Thrombocytopenia—Vincristine—lymphatic system cancer	4.53e-05	0.00127	CcSEcCtD
Zalcitabine—Oedema—Mitoxantrone—lymphatic system cancer	4.51e-05	0.00126	CcSEcCtD
Zalcitabine—Infection—Mitoxantrone—lymphatic system cancer	4.48e-05	0.00125	CcSEcCtD
Zalcitabine—Hyperhidrosis—Vincristine—lymphatic system cancer	4.48e-05	0.00125	CcSEcCtD
Zalcitabine—Shock—Mitoxantrone—lymphatic system cancer	4.44e-05	0.00124	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	4.42e-05	0.00124	CcSEcCtD
Zalcitabine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	4.42e-05	0.00124	CcSEcCtD
Zalcitabine—Urticaria—Bleomycin—lymphatic system cancer	4.42e-05	0.00124	CcSEcCtD
Zalcitabine—Anorexia—Vincristine—lymphatic system cancer	4.41e-05	0.00124	CcSEcCtD
Zalcitabine—Tachycardia—Mitoxantrone—lymphatic system cancer	4.4e-05	0.00123	CcSEcCtD
Zalcitabine—Body temperature increased—Bleomycin—lymphatic system cancer	4.39e-05	0.00123	CcSEcCtD
Zalcitabine—Insomnia—Carmustine—lymphatic system cancer	4.39e-05	0.00123	CcSEcCtD
Zalcitabine—Skin disorder—Mitoxantrone—lymphatic system cancer	4.38e-05	0.00123	CcSEcCtD
Zalcitabine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	4.36e-05	0.00122	CcSEcCtD
Zalcitabine—Mood swings—Methotrexate—lymphatic system cancer	4.33e-05	0.00121	CcSEcCtD
Zalcitabine—Dyspnoea—Carmustine—lymphatic system cancer	4.33e-05	0.00121	CcSEcCtD
Zalcitabine—Somnolence—Carmustine—lymphatic system cancer	4.31e-05	0.00121	CcSEcCtD
Zalcitabine—Anorexia—Mitoxantrone—lymphatic system cancer	4.3e-05	0.0012	CcSEcCtD
Zalcitabine—Ataxia—Methotrexate—lymphatic system cancer	4.3e-05	0.0012	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	4.22e-05	0.00118	CcSEcCtD
Zalcitabine—Decreased appetite—Carmustine—lymphatic system cancer	4.22e-05	0.00118	CcSEcCtD
Zalcitabine—Insomnia—Vincristine—lymphatic system cancer	4.19e-05	0.00117	CcSEcCtD
Zalcitabine—Pain—Carmustine—lymphatic system cancer	4.15e-05	0.00116	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	4.11e-05	0.00115	CcSEcCtD
Zalcitabine—Hypersensitivity—Bleomycin—lymphatic system cancer	4.09e-05	0.00115	CcSEcCtD
Zalcitabine—Decreased appetite—Vincristine—lymphatic system cancer	4.03e-05	0.00113	CcSEcCtD
Zalcitabine—Dyspnoea—Mitoxantrone—lymphatic system cancer	4.02e-05	0.00113	CcSEcCtD
Zalcitabine—Somnolence—Mitoxantrone—lymphatic system cancer	4.01e-05	0.00112	CcSEcCtD
Zalcitabine—Feeling abnormal—Carmustine—lymphatic system cancer	4e-05	0.00112	CcSEcCtD
Zalcitabine—Fatigue—Vincristine—lymphatic system cancer	3.99e-05	0.00112	CcSEcCtD
Zalcitabine—Asthenia—Bleomycin—lymphatic system cancer	3.99e-05	0.00112	CcSEcCtD
Zalcitabine—Dyspepsia—Mitoxantrone—lymphatic system cancer	3.97e-05	0.00111	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Carmustine—lymphatic system cancer	3.97e-05	0.00111	CcSEcCtD
Zalcitabine—Pain—Vincristine—lymphatic system cancer	3.96e-05	0.00111	CcSEcCtD
Zalcitabine—Pruritus—Bleomycin—lymphatic system cancer	3.93e-05	0.0011	CcSEcCtD
Zalcitabine—Decreased appetite—Mitoxantrone—lymphatic system cancer	3.92e-05	0.0011	CcSEcCtD
Zalcitabine—Eosinophilia—Methotrexate—lymphatic system cancer	3.91e-05	0.0011	CcSEcCtD
Zalcitabine—Fatigue—Mitoxantrone—lymphatic system cancer	3.89e-05	0.00109	CcSEcCtD
Zalcitabine—Pancreatitis—Methotrexate—lymphatic system cancer	3.87e-05	0.00108	CcSEcCtD
Zalcitabine—Pain—Mitoxantrone—lymphatic system cancer	3.86e-05	0.00108	CcSEcCtD
Zalcitabine—Body temperature increased—Carmustine—lymphatic system cancer	3.83e-05	0.00107	CcSEcCtD
Zalcitabine—Abdominal pain—Carmustine—lymphatic system cancer	3.83e-05	0.00107	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Vincristine—lymphatic system cancer	3.79e-05	0.00106	CcSEcCtD
Zalcitabine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	3.72e-05	0.00104	CcSEcCtD
Zalcitabine—Dysuria—Methotrexate—lymphatic system cancer	3.69e-05	0.00103	CcSEcCtD
Zalcitabine—Neutropenia—Methotrexate—lymphatic system cancer	3.69e-05	0.00103	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	3.69e-05	0.00103	CcSEcCtD
Zalcitabine—Abdominal pain—Vincristine—lymphatic system cancer	3.66e-05	0.00102	CcSEcCtD
Zalcitabine—Body temperature increased—Vincristine—lymphatic system cancer	3.66e-05	0.00102	CcSEcCtD
Zalcitabine—Photosensitivity reaction—Methotrexate—lymphatic system cancer	3.61e-05	0.00101	CcSEcCtD
Zalcitabine—Urticaria—Mitoxantrone—lymphatic system cancer	3.58e-05	0.001	CcSEcCtD
Zalcitabine—Hypersensitivity—Carmustine—lymphatic system cancer	3.57e-05	0.001	CcSEcCtD
Zalcitabine—Abdominal pain—Mitoxantrone—lymphatic system cancer	3.57e-05	0.000998	CcSEcCtD
Zalcitabine—Body temperature increased—Mitoxantrone—lymphatic system cancer	3.57e-05	0.000998	CcSEcCtD
Zalcitabine—Vomiting—Bleomycin—lymphatic system cancer	3.53e-05	0.000989	CcSEcCtD
Zalcitabine—Depression—Methotrexate—lymphatic system cancer	3.51e-05	0.000983	CcSEcCtD
Zalcitabine—Rash—Bleomycin—lymphatic system cancer	3.5e-05	0.000981	CcSEcCtD
Zalcitabine—Dermatitis—Bleomycin—lymphatic system cancer	3.5e-05	0.00098	CcSEcCtD
Zalcitabine—Asthenia—Carmustine—lymphatic system cancer	3.48e-05	0.000974	CcSEcCtD
Zalcitabine—Hypersensitivity—Vincristine—lymphatic system cancer	3.41e-05	0.000955	CcSEcCtD
Zalcitabine—Epistaxis—Methotrexate—lymphatic system cancer	3.32e-05	0.00093	CcSEcCtD
Zalcitabine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	3.32e-05	0.00093	CcSEcCtD
Zalcitabine—Asthenia—Vincristine—lymphatic system cancer	3.32e-05	0.00093	CcSEcCtD
Zalcitabine—Diarrhoea—Carmustine—lymphatic system cancer	3.32e-05	0.000929	CcSEcCtD
Zalcitabine—Asthenia—Mitoxantrone—lymphatic system cancer	3.24e-05	0.000906	CcSEcCtD
Zalcitabine—Dizziness—Carmustine—lymphatic system cancer	3.21e-05	0.000898	CcSEcCtD
Zalcitabine—Diarrhoea—Vincristine—lymphatic system cancer	3.17e-05	0.000887	CcSEcCtD
Zalcitabine—Hepatitis—Methotrexate—lymphatic system cancer	3.16e-05	0.000885	CcSEcCtD
Zalcitabine—Pharyngitis—Methotrexate—lymphatic system cancer	3.14e-05	0.000879	CcSEcCtD
Zalcitabine—Diarrhoea—Mitoxantrone—lymphatic system cancer	3.09e-05	0.000864	CcSEcCtD
Zalcitabine—Vomiting—Carmustine—lymphatic system cancer	3.08e-05	0.000863	CcSEcCtD
Zalcitabine—Dizziness—Vincristine—lymphatic system cancer	3.06e-05	0.000857	CcSEcCtD
Zalcitabine—Rash—Carmustine—lymphatic system cancer	3.06e-05	0.000856	CcSEcCtD
Zalcitabine—Dermatitis—Carmustine—lymphatic system cancer	3.06e-05	0.000855	CcSEcCtD
Zalcitabine—Visual impairment—Methotrexate—lymphatic system cancer	3.05e-05	0.000853	CcSEcCtD
Zalcitabine—Headache—Carmustine—lymphatic system cancer	3.04e-05	0.000851	CcSEcCtD
Zalcitabine—Eye disorder—Methotrexate—lymphatic system cancer	2.96e-05	0.000827	CcSEcCtD
Zalcitabine—Tinnitus—Methotrexate—lymphatic system cancer	2.95e-05	0.000825	CcSEcCtD
Zalcitabine—Vomiting—Vincristine—lymphatic system cancer	2.94e-05	0.000824	CcSEcCtD
Zalcitabine—Rash—Vincristine—lymphatic system cancer	2.92e-05	0.000817	CcSEcCtD
Zalcitabine—Dermatitis—Vincristine—lymphatic system cancer	2.92e-05	0.000817	CcSEcCtD
Zalcitabine—Headache—Vincristine—lymphatic system cancer	2.9e-05	0.000812	CcSEcCtD
Zalcitabine—Vomiting—Mitoxantrone—lymphatic system cancer	2.87e-05	0.000803	CcSEcCtD
Zalcitabine—Rash—Mitoxantrone—lymphatic system cancer	2.84e-05	0.000796	CcSEcCtD
Zalcitabine—Dermatitis—Mitoxantrone—lymphatic system cancer	2.84e-05	0.000795	CcSEcCtD
Zalcitabine—Chills—Methotrexate—lymphatic system cancer	2.84e-05	0.000794	CcSEcCtD
Zalcitabine—Headache—Mitoxantrone—lymphatic system cancer	2.83e-05	0.000791	CcSEcCtD
Zalcitabine—Alopecia—Methotrexate—lymphatic system cancer	2.79e-05	0.000782	CcSEcCtD
Zalcitabine—Dysgeusia—Methotrexate—lymphatic system cancer	2.7e-05	0.000755	CcSEcCtD
Zalcitabine—Back pain—Methotrexate—lymphatic system cancer	2.66e-05	0.000745	CcSEcCtD
Zalcitabine—Vision blurred—Methotrexate—lymphatic system cancer	2.59e-05	0.000726	CcSEcCtD
Zalcitabine—Ill-defined disorder—Methotrexate—lymphatic system cancer	2.55e-05	0.000715	CcSEcCtD
Zalcitabine—Anaemia—Methotrexate—lymphatic system cancer	2.54e-05	0.000712	CcSEcCtD
Zalcitabine—Malaise—Methotrexate—lymphatic system cancer	2.48e-05	0.000695	CcSEcCtD
Zalcitabine—Vertigo—Methotrexate—lymphatic system cancer	2.47e-05	0.000692	CcSEcCtD
Zalcitabine—Leukopenia—Methotrexate—lymphatic system cancer	2.46e-05	0.00069	CcSEcCtD
Zalcitabine—Cough—Methotrexate—lymphatic system cancer	2.4e-05	0.000672	CcSEcCtD
Zalcitabine—Convulsion—Methotrexate—lymphatic system cancer	2.39e-05	0.000668	CcSEcCtD
Zalcitabine—Arthralgia—Methotrexate—lymphatic system cancer	2.34e-05	0.000656	CcSEcCtD
Zalcitabine—Myalgia—Methotrexate—lymphatic system cancer	2.34e-05	0.000656	CcSEcCtD
Zalcitabine—Discomfort—Methotrexate—lymphatic system cancer	2.32e-05	0.000648	CcSEcCtD
Zalcitabine—Confusional state—Methotrexate—lymphatic system cancer	2.27e-05	0.000634	CcSEcCtD
Zalcitabine—Infection—Methotrexate—lymphatic system cancer	2.23e-05	0.000625	CcSEcCtD
Zalcitabine—Thrombocytopenia—Methotrexate—lymphatic system cancer	2.2e-05	0.000616	CcSEcCtD
Zalcitabine—Skin disorder—Methotrexate—lymphatic system cancer	2.18e-05	0.000611	CcSEcCtD
Zalcitabine—Hyperhidrosis—Methotrexate—lymphatic system cancer	2.17e-05	0.000608	CcSEcCtD
Zalcitabine—Anorexia—Methotrexate—lymphatic system cancer	2.14e-05	0.0006	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	2.05e-05	0.000573	CcSEcCtD
Zalcitabine—Insomnia—Methotrexate—lymphatic system cancer	2.03e-05	0.000569	CcSEcCtD
Zalcitabine—Dyspnoea—Methotrexate—lymphatic system cancer	2e-05	0.000561	CcSEcCtD
Zalcitabine—Somnolence—Methotrexate—lymphatic system cancer	2e-05	0.000559	CcSEcCtD
Zalcitabine—Dyspepsia—Methotrexate—lymphatic system cancer	1.98e-05	0.000554	CcSEcCtD
Zalcitabine—Decreased appetite—Methotrexate—lymphatic system cancer	1.95e-05	0.000547	CcSEcCtD
Zalcitabine—Fatigue—Methotrexate—lymphatic system cancer	1.94e-05	0.000542	CcSEcCtD
Zalcitabine—Pain—Methotrexate—lymphatic system cancer	1.92e-05	0.000538	CcSEcCtD
Zalcitabine—Feeling abnormal—Methotrexate—lymphatic system cancer	1.85e-05	0.000518	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	1.84e-05	0.000514	CcSEcCtD
Zalcitabine—Urticaria—Methotrexate—lymphatic system cancer	1.79e-05	0.0005	CcSEcCtD
Zalcitabine—Abdominal pain—Methotrexate—lymphatic system cancer	1.78e-05	0.000497	CcSEcCtD
Zalcitabine—Body temperature increased—Methotrexate—lymphatic system cancer	1.78e-05	0.000497	CcSEcCtD
Zalcitabine—Hypersensitivity—Methotrexate—lymphatic system cancer	1.66e-05	0.000463	CcSEcCtD
Zalcitabine—Asthenia—Methotrexate—lymphatic system cancer	1.61e-05	0.000451	CcSEcCtD
Zalcitabine—Pruritus—Methotrexate—lymphatic system cancer	1.59e-05	0.000445	CcSEcCtD
Zalcitabine—Diarrhoea—Methotrexate—lymphatic system cancer	1.54e-05	0.00043	CcSEcCtD
Zalcitabine—Dizziness—Methotrexate—lymphatic system cancer	1.49e-05	0.000416	CcSEcCtD
Zalcitabine—Vomiting—Methotrexate—lymphatic system cancer	1.43e-05	0.0004	CcSEcCtD
Zalcitabine—Rash—Methotrexate—lymphatic system cancer	1.42e-05	0.000397	CcSEcCtD
Zalcitabine—Dermatitis—Methotrexate—lymphatic system cancer	1.42e-05	0.000396	CcSEcCtD
Zalcitabine—Headache—Methotrexate—lymphatic system cancer	1.41e-05	0.000394	CcSEcCtD
